GlassScriptPhysician profile
Nita Abraham
NPI 1366934556
$4,665.31
in general payments reported to CMS, 2019-2025
24 companies · $1,220 in 2025
The $1,220 reported for 2025 was more than what 88% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $660 · 2022: $701 · 2023: $958 · 2024: $1,126 · 2025: $1,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,304.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,057.25 | 2021-2025 | Lifevest |
| Boston Scientific Corporation | $717.80 | 2022-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $540.09 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $406.08 | 2021-2025 | Farxiga, Lokelma, Brilinta |
| Amgen INC. | $325.99 | 2023-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $264.46 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Janssen Pharmaceuticals, INC | $176.89 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.66 | 2022-2025 | Jardiance |
| Bridgebio Pharma, INC. | $134.63 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $128.10 | 2025 | Amvuttra |
| Abbott Laboratories | $113.42 | 2021-2025 | Triclip, Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $103.93 | 2025 | |
| Pfizer INC. | $97.27 | 2022-2025 | |
| Impulse Dynamics (USA) INC. | $80.56 | 2022-2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $73.26 | 2021-2024 | Eliquis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $72.91 | 2023 | |
| Novo Nordisk INC | $57.93 | 2025 | Wegovy |
| Gilead Sciences, INC. | $33.07 | 2021 | |
| Merck Sharp & Dohme LLC | $24.16 | 2023 | Verquvo, Belsomra |
| Kestra Medical Technology Services, INC. | $21.64 | 2023 | Assure Wcd |
| Esperion Therapeutics, INC. | $21.43 | 2022 | |
| Celgene Corporation | $17.55 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $16.72 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nita Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.